drugset

drugset / Trial / NCT01223027

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

NCT01223027 ↗

Phase 3 Completed 564 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.

Timeline

Start: 2011-03
Primary completion: 2014-06
Completion: 2014-06

Publications

Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grunwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Mar;15(3):286-96. doi: 10.1016/S1470-2045(14)70030-0. Epub 2014 Feb 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dovitinib	Small molecule	500 mg	Oral
Comparator	Sorafenib	Small molecule	400 mg	Oral

Indications